Jove
Visualize
Contact Us

Related Experiment Videos

Telithromycin: the first ketolide antimicrobial.

Megan Nguyen1, Eunice P Chung

  • 1Western University of Health Sciences, College of Pharmacy, Pomona, CA 91766, USA. megannguyen@westernu.edu

Clinical Therapeutics
|October 4, 2005
PubMed
Summary

Telithromycin, a novel ketolide antibiotic, demonstrates efficacy in treating respiratory tract infections like pneumonia and bronchitis. It shows promise against resistant bacteria, offering a valuable option for adults, especially in outpatient settings.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing the State of Published HIV Research Concerning Sexual Minority Women: A Global English Language Scoping Review.

LGBT health·2026
Same author

A bibliometric analysis describing the global scope of pharmacist roles (2000-2024).

Journal of the American Pharmacists Association : JAPhA·2026
Same author

The ASD Risk Gene <i>D5Ertd579e</i> Regulates Synaptic Plasticity and Selective Autism-Related Behaviors.

bioRxiv : the preprint server for biology·2026
Same author

2025-2026 Academic Affairs Committee Report: Advancing Competency-Based Pharmacy Education and Academic Coaching.

American journal of pharmaceutical education·2026
Same author

A Bibliometric Analysis of Pharmacist-Delivered Care: Global Trends, Outcomes, and Practice Settings (2000-2024).

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

"A chance to open my heart": Protective factors for mental health in left-behind family members of Nepalese labor migrants and their implications for future psychosocial interventions.

PLOS global public health·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Medicine

Background:

  • Telithromycin is the first approved ketolide antibiotic by the US FDA.
  • Approved for community-acquired pneumonia (CAP), chronic bronchitis exacerbations (AECB), and acute maxillary sinusitis (AMS).

Purpose of the Study:

  • To review telithromycin's mechanism of action, antimicrobial activity, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, and drug interactions.
  • To assess its role in treating common respiratory tract infections.

Main Methods:

  • Literature search of MEDLINE (1990-2005) and conference abstracts.
  • Review of manufacturer's briefing document for the FDA Anti-infective Drugs Advisory Committee.

Main Results:

Related Experiment Videos

  • Telithromycin covers key typical and atypical respiratory pathogens, including resistant Streptococcus pneumoniae and Haemophilus influenzae.
  • Clinical trials showed comparable efficacy to comparators for CAP, AECB, and AMS.
  • Adverse events were mostly mild-to-moderate; potential for hepatic transaminase elevations and QTc prolongation noted. Strong CYP3A4 inhibition requires monitoring for drug interactions.

Conclusions:

  • Telithromycin is a viable option for empiric treatment of adult community-acquired respiratory tract infections (RTIs).
  • Particularly useful in outpatient settings with high rates of resistant S. pneumoniae.
  • An alternative for beta-lactam allergic patients or those with resistance to other therapies.